Neurogene (NGNE) announced that the first participant was dosed in the Embolden registrational clinical trial of NGN-401, a gene therapy in development for the treatment of Rett syndrome. NGN-401 has the potential to be a best-in-class and first-in-class gene therapy for Rett syndrome, a neurodevelopmental disorder with significant unmet medical need.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NGNE:
- Neurogene Begins Dosing in Rett Syndrome Trial
- Neurogene price target raised to $65 from $45 at H.C. Wainwright
- Neurogene Inc.’s NGN-401: A Promising Gene Therapy for Rett Syndrome
- Neurogene’s Strategic Advances and Expanded Embolden Trial Drive Buy Rating
- Neurogene’s Favorable Position in CNS Gene Therapy: Buy Rating Backed by Strategic Advantages and Competitive Valuation